FDRC1 and Follicular Dendritic Cell Signaling Pathways
FDRC1 and Follicular Dendritic Cell Signaling Pathways
批准号:
8288880
负责人:
Edward A Clark
金额:
$45.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 2014-06-30
关键词:
AffectAftercareAlbers-Schonberg diseaseAntigen-Presenting CellsAntigensApoptosisAutoimmune DiseasesBindingBlood VesselsBone DiseasesC-Type LectinsCaspaseCell DeathCell MaturationCell SurvivalCell physiologyCellsChronicCommunicable DiseasesCommunicationCoronary ArteriosclerosisCytomegalovirusDataDefectDelayed HypersensitivityDendritic CellsDevelopmentDiseaseEndotoxemiaEstradiolEstrogensExperimental Autoimmune EncephalomyelitisFamilyFollicular Dendritic CellsHomeostasisHumanImmune System DiseasesImmune responseImmune systemImmunityImmunologistIn VitroInflammatoryInflammatory ResponseInjection of therapeutic agentLeadLifeLigandsLipopolysaccharidesLongevityLymphoidMeasles virusMediatingMultiple SclerosisMusMutationOsteoporosisPathway interactionsPatientsPattern recognition receptorPeptidesPeripheralPlayProcessProductionProteinsRegulationResearch PersonnelResistanceRheumatoid ArthritisRiskRoleSentinelSerumSeveritiesSignal PathwaySignal TransductionSiteSystemSystemic Lupus ErythematosusT-Cell ActivationT-LymphocyteTNFRSF5 geneTNFSF10 geneTRANCE proteinTestingToll-like receptorsTumor Necrosis Factor ReceptorTumor Necrosis Factor-alphaTumor necrosis factor receptor 11bVirusWomanautoimmune lymphoproliferative syndromebone metabolismcalcificationcaspase-10cell motilitychemokine receptorcytokineimmunoregulationin vitro testingin vivoinsightinterestkillingslymph nodesmembermenoverexpressionpathogenprogramspromoterreceptorresponse
中文摘要
树突状细胞(dc)有助于协调和桥梁先天和适应性免疫反应。dc在很大程度上是这样
英文摘要
Dendritic cells (DCs) help to coordinate and bridge innate and adaptive immune responses. DCs for the most part are
short lived; how long they live and where may influence whether they induce immunity, tolerance or autoimmune
disease. DC fate and cytokine production are regulated in part by RANK (receptor activator ofNF-IcB ligand), receptors
for TRAIL (tumor necrosis factor-alpha-related papooses-inducing ligand) and the soluble 'decoy' receptor
osteoprotegerin (OPG), which binds RANK ligand (RANKL) and TRAIL. Our data suggest that DC cytokine
production and survival are dysregulated in the absence of OPG. We plan to define the role the RANKL/RANK/OPG
system plays in regulating DCs. We wiU test the hypothesis that OPG regulates dendritic cell survival by modulating
the RANKL/RANK and TRAIL/TRAIL receptor pathways. We will test whether OPG -/- or RANK -/- DCs differ from
wildtype DCs in their survival in vitro or in vivo. The effect of overexpressing the survival protein Bcl-2 on the DC-
restricted CD1 lc promoter will be evaluated in OPG -/- and RANK -/- mice. We predict that by altering the lifespan of
DCs in vivo, that underlying defects in disease, bone homeostasis and peripheral lymphoid development will be altered.
We will also test the hypothesis that human immature DCs (iDCs) and mature DCs (mDCs) differ in how they are
regulated by the RANK/OPG/TRAIL receptor pathways and by caspases. Next we will test the hypothesis that OPG
regulates the profile and levels of cytoldnes produced by DC subsets. We will define how the absence of OPG or
RANK affects cytokine production in vitro and test whether the cytokine dysregulation in OPG -/- and RANK -/- mice
influences in vivo responses to lipopolysaccharide (LPS) and peptide-induced experimental autoimmune
encephalomyelitis (EAE). The expression of OPG, RANKL and TRAIL receptors is regulated by 17-13-estradiol (E2).
Therefore, we will test the hypotheses that E2 modulates peptide-induced EAE, DC survival and cytokine production
via an OPG-<lependent pathway. If OPG is required for E2 to downregulate EAE, we will explore if this is due in part to
direct effects of E2 on DCs. Further understanding of how DC longevity and cytokine secretion are regulated may lead
to new insights into the causes of and treatments for chronic immunologic diseases like rheumatoid arthritis and
multiple sclerosis. The proposed studies may also contribute to understanding of how E2 and OPG contribute to the
development of inflammatory immune responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Novel CD180-Based Cancer Immunotherapeutics
-
批准号:10381384
-
项目类别:
-
资助金额:$39.8万
-
财政年份:2022
-
负责人:Edward A Clark
-
依托单位:
Mouse Resource Core
-
批准号:8811087
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Edward A Clark
-
依托单位:
Establishing and characterizing BAFF RFP reporter and BAFF knockin mice
-
批准号:8468991
-
项目类别:
-
资助金额:$8.9万
-
财政年份:2012
-
负责人:Edward A Clark
-
依托单位:
Establishing and characterizing BAFF RFP reporter and BAFF knockin mice
-
批准号:8353277
-
项目类别:
-
资助金额:$8.9万
-
财政年份:2012
-
负责人:Edward A Clark
-
依托单位:
Regulation of B cell responses to West Nile Virus Infections
-
批准号:7746284
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2009
-
负责人:Edward A Clark
-
依托单位:
Dendritic cells, Mucosal Immunity and C-type Lectins
-
批准号:6852485
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2005
-
负责人:Edward A Clark
-
依托单位:
Dendritic cells, Mucosal Immunity and C-type Lectins
-
批准号:7410149
-
项目类别:
-
资助金额:$35.63万
-
财政年份:2005
-
负责人:Edward A Clark
-
依托单位:
Dendritic cells, Mucosal Immunity and C-type Lectins
-
批准号:7596450
-
项目类别:
-
资助金额:$35.63万
-
财政年份:2005
-
负责人:Edward A Clark
-
依托单位:
Dendritic cells, Mucosal Immunity and C-type Lectins
-
批准号:7223471
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2005
-
负责人:Edward A Clark
-
依托单位:
Dendritic cells, Mucosal Immunity and C-type Lectins
-
批准号:7050592
-
项目类别:
-
资助金额:$37.11万
-
财政年份:2005
-
负责人:Edward A Clark
-
依托单位:
Dendritic Cell-Associated C-Type Lectins
-
批准号:7224169
-
项目类别:
-
资助金额:$34.13万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
Dendritic Cell-Associated C-Type Lectins
-
批准号:6743213
-
项目类别:
-
资助金额:$36.0万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
Dendritic Cell-Associated C-Type Lectins
-
批准号:7056670
-
项目类别:
-
资助金额:$35.15万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
B CELL IMMUNOTHERAPY IN MACAQUES
-
批准号:6940082
-
项目类别:
-
资助金额:$14.14万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
Dendritic Cell-Associated C-Type Lectins
-
批准号:6610827
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
Dendritic Cell-Associated C-Type Lectins
-
批准号:8299146
-
项目类别:
-
资助金额:$42.92万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
Dendritic Cell-Associated C-Type Lectins
-
批准号:8096672
-
项目类别:
-
资助金额:$42.94万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
Programming protective immunity by targeting antigens to the CD180 receptor
-
批准号:8979329
-
项目类别:
-
资助金额:$43.5万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
Dendritic Cell-Associated C-Type Lectins
-
批准号:6891901
-
项目类别:
-
资助金额:$36.0万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
Dendritic Cell-Associated C-Type Lectins
-
批准号:8481497
-
项目类别:
-
资助金额:$40.34万
-
财政年份:2003
-
负责人:Edward A Clark
-
依托单位:
海外基金